FDA Issues Drug Safety Communication on Azithromycin (Zithromax or Zmax)

The FDA issued a Drug Safety Communication announcement regarding the drug azithromycin (Zithromax or Zmax) warning that it may lead to potentially fatal irregular heart rhythm. According to the FDA announcement, patients who are more likely are those with “existing QT interval prolongation, low blood levels of potassium or magnesium, a slower than normal heart rate, or use of certain drugs used to treat abnormal heart rhythms, or arrhythmias.” Read the FDA’s statement.

Clinical Topics: Arrhythmias and Clinical EP, Implantable Devices, EP Basic Science

Keywords: Azithromycin, Cardiac Complexes, Premature, Heart Conduction System, Heart Rate, Magnesium, Potassium

< Back to Listings